Perhaps one of the most important psychedelic science articles published in 2021 came when psychopharmacologist Suresh Muthukumaraswamy and colleagues Anna Forsythe and Thomas Lumley called out the big elephant in the room of psychedelic clinical trials. The researchers suggested many modern psychedelic clinical trials may be generating overstated results because the nature of the drugs make it virtually impossible to have an effective placebo group. The article ultimately offered a number of suggestions that could improve the field.
Is the Placebo Problem at the Heart of Modern Psychedelic Clinical Research?
Taking entheogens can be like air travel: people do it all the time, it’s usually fine, but when it’s not fine, it’s sometimes very bad. We’ve been there. And that’s where an experienced GUIDE can make the difference in the outcome.
I’m available by phone if you or someone you know wants to ask questions of ANY nature. Use this link to schedule a call HERE.